Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia

The purpose of this study was to evaluate the impact of switching patients being treated for acute lymphoblastic leukemia (ALL) from vincristine to bortezomib. A total of 20 patients with ALL were switched from vincristine to bortezomib (1.3 mg/m/dose) because of worsening neuropathy despite physica...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of pediatric hematology/oncology Ročník 41; číslo 6; s. 457
Hlavní autoři:	Joshi, Jaitri, Tanner, Lynn, Gilchrist, Laura, Bostrom, Bruce
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.08.2019
Témata:	Adolescent Adult Antineoplastic Agents - therapeutic use Antineoplastic Agents, Phytogenic - adverse effects Bortezomib - therapeutic use Child Child, Preschool Drug Substitution - statistics & numerical data Female Follow-Up Studies Humans Male Nervous System Diseases - chemically induced Nervous System Diseases - pathology Nervous System Diseases - prevention & control Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Retrospective Studies Vincristine - adverse effects Young Adult
ISSN:	1536-3678, 1536-3678
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!